Executive Summary
Digital maturity is becoming a competitive differentiator across the pharmaceutical and biotechnology industries. While many organizations invest in...
Novartis reported late-stage clinical trial failures for two experimental medicines in September, including del-desiran, which was being developed for...
BioNTech and DualityBio have reported topline results from DYNASTY-Breast02, a global phase 3 clinical trial evaluating trastuzumab pamirtecan (t-pam)...
Executive Summary
Digital therapeutics (DTx) are evolving beyond standalone software interventions toward more personalized, connected, and clinically integrated treatment experiences....